Clinical Features and Outcomes of Delayed-onset Primary Cytomegalovirus Disease in Cardiac Transplant Recipients

Supha Kijpittayarit-Arthurs, Albert J. Eid, Walter K Kremers, Rachel A. Pedersen, Ross A. Dierkhising, Robin Patel, Raymund R Razonable

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Cytomegalovirus (CMV)-seronegative recipients of cardiac allografts from CMV-seropositive donors (CMV D+/R-) are at highest risk of CMV disease after transplantation. This study was conducted to investigate the incidence, clinical features, risk factors and outcome of delayed-onset primary CMV disease in cardiac recipients who received anti-CMV prophylaxis. Methods: This study enrolled all CMV D+/R- cardiac recipients during the period from 2000 to 2004. The medical records of patients were reviewed to assess clinical variables and outcomes. The data were analyzed using descriptive statistics and survival analysis. Results: During the 5-year study period, a total of 31 cardiac recipients had CMV D+/R- serostatus (mean age ± SD: 49.2 ± 13.7 years; 74% male). All patients received oral ganciclovir (n = 6) or valganciclovir (n = 25) prophylaxis for a median duration of 95 days (interquartile range: 90 to 100). No breakthrough CMV disease was observed. However, 9 (29%) patients developed delayed-onset primary CMV disease (3 with CMV syndrome, 6 with gastrointestinal disease) during the period from 120 to 444 days after transplantation. No demographic or clinical variable was significantly associated with delayed-onset primary CMV disease. However, acute rejection with a severity of Grade ≥2 showed a trend toward association with CMV disease (hazards ratio: 2.46; 95% confidence interval: 0.66 to 9.2; p = 0.18). During the mean (±SD) follow-up period of 2.9 (±1.68) years, 3 patients died. CMV disease was not associated with all-cause mortality. Conclusions: In the contemporary era of anti-viral prophylaxis, delayed-onset primary CMV disease remains a common complication among CMV D+/R- cardiac recipients. This finding warrants a better strategy for CMV prevention.

Original languageEnglish (US)
Pages (from-to)1019-1024
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume26
Issue number10
DOIs
StatePublished - Oct 2007

Fingerprint

Cytomegalovirus
Heart Diseases
Transplant Recipients
Transplantation
Ganciclovir
Gastrointestinal Diseases
Survival Analysis
Medical Records
Allografts

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Clinical Features and Outcomes of Delayed-onset Primary Cytomegalovirus Disease in Cardiac Transplant Recipients. / Kijpittayarit-Arthurs, Supha; Eid, Albert J.; Kremers, Walter K; Pedersen, Rachel A.; Dierkhising, Ross A.; Patel, Robin; Razonable, Raymund R.

In: Journal of Heart and Lung Transplantation, Vol. 26, No. 10, 10.2007, p. 1019-1024.

Research output: Contribution to journalArticle

@article{add9a606ce4a4bfda4e832329e18cb8e,
title = "Clinical Features and Outcomes of Delayed-onset Primary Cytomegalovirus Disease in Cardiac Transplant Recipients",
abstract = "Background: Cytomegalovirus (CMV)-seronegative recipients of cardiac allografts from CMV-seropositive donors (CMV D+/R-) are at highest risk of CMV disease after transplantation. This study was conducted to investigate the incidence, clinical features, risk factors and outcome of delayed-onset primary CMV disease in cardiac recipients who received anti-CMV prophylaxis. Methods: This study enrolled all CMV D+/R- cardiac recipients during the period from 2000 to 2004. The medical records of patients were reviewed to assess clinical variables and outcomes. The data were analyzed using descriptive statistics and survival analysis. Results: During the 5-year study period, a total of 31 cardiac recipients had CMV D+/R- serostatus (mean age ± SD: 49.2 ± 13.7 years; 74{\%} male). All patients received oral ganciclovir (n = 6) or valganciclovir (n = 25) prophylaxis for a median duration of 95 days (interquartile range: 90 to 100). No breakthrough CMV disease was observed. However, 9 (29{\%}) patients developed delayed-onset primary CMV disease (3 with CMV syndrome, 6 with gastrointestinal disease) during the period from 120 to 444 days after transplantation. No demographic or clinical variable was significantly associated with delayed-onset primary CMV disease. However, acute rejection with a severity of Grade ≥2 showed a trend toward association with CMV disease (hazards ratio: 2.46; 95{\%} confidence interval: 0.66 to 9.2; p = 0.18). During the mean (±SD) follow-up period of 2.9 (±1.68) years, 3 patients died. CMV disease was not associated with all-cause mortality. Conclusions: In the contemporary era of anti-viral prophylaxis, delayed-onset primary CMV disease remains a common complication among CMV D+/R- cardiac recipients. This finding warrants a better strategy for CMV prevention.",
author = "Supha Kijpittayarit-Arthurs and Eid, {Albert J.} and Kremers, {Walter K} and Pedersen, {Rachel A.} and Dierkhising, {Ross A.} and Robin Patel and Razonable, {Raymund R}",
year = "2007",
month = "10",
doi = "10.1016/j.healun.2007.07.016",
language = "English (US)",
volume = "26",
pages = "1019--1024",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Clinical Features and Outcomes of Delayed-onset Primary Cytomegalovirus Disease in Cardiac Transplant Recipients

AU - Kijpittayarit-Arthurs, Supha

AU - Eid, Albert J.

AU - Kremers, Walter K

AU - Pedersen, Rachel A.

AU - Dierkhising, Ross A.

AU - Patel, Robin

AU - Razonable, Raymund R

PY - 2007/10

Y1 - 2007/10

N2 - Background: Cytomegalovirus (CMV)-seronegative recipients of cardiac allografts from CMV-seropositive donors (CMV D+/R-) are at highest risk of CMV disease after transplantation. This study was conducted to investigate the incidence, clinical features, risk factors and outcome of delayed-onset primary CMV disease in cardiac recipients who received anti-CMV prophylaxis. Methods: This study enrolled all CMV D+/R- cardiac recipients during the period from 2000 to 2004. The medical records of patients were reviewed to assess clinical variables and outcomes. The data were analyzed using descriptive statistics and survival analysis. Results: During the 5-year study period, a total of 31 cardiac recipients had CMV D+/R- serostatus (mean age ± SD: 49.2 ± 13.7 years; 74% male). All patients received oral ganciclovir (n = 6) or valganciclovir (n = 25) prophylaxis for a median duration of 95 days (interquartile range: 90 to 100). No breakthrough CMV disease was observed. However, 9 (29%) patients developed delayed-onset primary CMV disease (3 with CMV syndrome, 6 with gastrointestinal disease) during the period from 120 to 444 days after transplantation. No demographic or clinical variable was significantly associated with delayed-onset primary CMV disease. However, acute rejection with a severity of Grade ≥2 showed a trend toward association with CMV disease (hazards ratio: 2.46; 95% confidence interval: 0.66 to 9.2; p = 0.18). During the mean (±SD) follow-up period of 2.9 (±1.68) years, 3 patients died. CMV disease was not associated with all-cause mortality. Conclusions: In the contemporary era of anti-viral prophylaxis, delayed-onset primary CMV disease remains a common complication among CMV D+/R- cardiac recipients. This finding warrants a better strategy for CMV prevention.

AB - Background: Cytomegalovirus (CMV)-seronegative recipients of cardiac allografts from CMV-seropositive donors (CMV D+/R-) are at highest risk of CMV disease after transplantation. This study was conducted to investigate the incidence, clinical features, risk factors and outcome of delayed-onset primary CMV disease in cardiac recipients who received anti-CMV prophylaxis. Methods: This study enrolled all CMV D+/R- cardiac recipients during the period from 2000 to 2004. The medical records of patients were reviewed to assess clinical variables and outcomes. The data were analyzed using descriptive statistics and survival analysis. Results: During the 5-year study period, a total of 31 cardiac recipients had CMV D+/R- serostatus (mean age ± SD: 49.2 ± 13.7 years; 74% male). All patients received oral ganciclovir (n = 6) or valganciclovir (n = 25) prophylaxis for a median duration of 95 days (interquartile range: 90 to 100). No breakthrough CMV disease was observed. However, 9 (29%) patients developed delayed-onset primary CMV disease (3 with CMV syndrome, 6 with gastrointestinal disease) during the period from 120 to 444 days after transplantation. No demographic or clinical variable was significantly associated with delayed-onset primary CMV disease. However, acute rejection with a severity of Grade ≥2 showed a trend toward association with CMV disease (hazards ratio: 2.46; 95% confidence interval: 0.66 to 9.2; p = 0.18). During the mean (±SD) follow-up period of 2.9 (±1.68) years, 3 patients died. CMV disease was not associated with all-cause mortality. Conclusions: In the contemporary era of anti-viral prophylaxis, delayed-onset primary CMV disease remains a common complication among CMV D+/R- cardiac recipients. This finding warrants a better strategy for CMV prevention.

UR - http://www.scopus.com/inward/record.url?scp=34848820267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848820267&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2007.07.016

DO - 10.1016/j.healun.2007.07.016

M3 - Article

VL - 26

SP - 1019

EP - 1024

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 10

ER -